Analysis Tools
hematopoietic system
|
• at 18 weeks in pIpC-treated mice
|
|
• reduced frequency and absolute number of LSK cells as early as 4 weeks in pIpC-treated mice
• reduced overall numbers of hematopoietic stem cells at 18 weeks in pIpC-treated mice
|
|
• at 18 weeks in pIpC-treated mice
|
|
• at 18 weeks in pIpC-treated mice
|
|
• in reconstitution and replicative stress assays, pIpC-treated hematopoietic stem cells exhibit impaired engraftment and functionality with reduced production of myeloid lineages and a bias toward differentiation compared with control cells
|
immune system
| N |
• pIpC-treated mice exhibit normal frequencies of mature myeloid cell types and B and T cells in the bone marrow and spleen
|
|
• at 18 weeks in pIpC-treated mice
|
|
• at 18 weeks in pIpC-treated mice
|
